You are here

Selective LPA1 receptor antagonists as agents in prevention of renal fibrosis

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43DK092005-01A1
Agency Tracking Number: R43DK092005
Amount: $389,603.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIDDK
Solicitation Number: PA11-096
Solicitation Year: 2012
Award Year: 2012
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
10225 Barnes Canyon Road suite A104
United States
DUNS: 963248807
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (619) 917-0639
Business Contact
Phone: (858) 337-1801
Research Institution

DESCRIPTION (provided by applicant): The ultimate goal of our project is to develop novel therapeutics effective in chronic kidney diseases that normally develop fibrosis, lead to end stage renal disease and require renal replacement therapy. This will beachieved by identifying novel selective functional antagonists for the lysophosphatidic acid (LPA) type 1 receptor. Our drug discovery approach will synthesize novel compounds free of drug-drug interaction risks that demonstrate selective, functional antagonism of the LPA-1 receptor. Their effectiveness will be confirmed using a series of high throughput cell-based assays. Candidate molecules will then be evaluated for their ability to prevent the progression of renal fibrosis in a unilateral ureteral obstruction (UUO) animal model. The intent of this Phase 1 study is to identify at least one novel series of molecules for lead optimization in a Phase 2 program. PUBLIC HEALTH RELEVANCE: The objective is to discover and develop new drugs for treatingchronic kidney diseases that involve renal fibrosis, a significant cause of mortality.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government